Peptide Romania
cognitive

Selank

Anxiolytic neuropeptide with GABAergic and immunomodulatory signalling profile.

Dovezi
Moderate
T½
Short
Categorie
cognitive
Status
Regional Rx

Evaluarea dovezilor

Baza de dovezi

Moderate66%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Anxiolytic neuropeptide with GABAergic and immunomodulatory signalling profile.

T½Short
StatusRegional Rx
Categoriecognitive
DoveziModerate

Întrebări frecvente

Ce trebuie să știi

Anxiolytic neuropeptide with GABAergic and immunomodulatory signalling profile.
Selank has Moderate evidence. Human or animal studies show positive signals, but some methodological variation or conflicting data exists. Further large-scale trials are needed to confirm findings.
The half-life of Selank is Short. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
Selank is currently classified as: Regional Rx. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Anxiolytic neuropeptide with GABAergic and immunomodulatory signalling profile.
Înapoi la peptide